跳至主要内容
临床试验/NCT07195955
NCT07195955已完成不适用

The Effect of Cold Spray Application in Reducing Pain and Ecchymosis in Patients Receiving Low Molecular Weight Heparin Prophylaxis After Orthopedic Surgery

Kocaeli University1 个研究点 分布在 1 个国家目标入组 101 人开始时间: 2024年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
101
试验地点
1
主要终点
Pain Intensity

研究概览

简要总结

Heparin is a widely used anticoagulant for thrombosis prevention, and low molecular weight heparin (LMWH) has become the preferred option due to its higher bioavailability, strong antithrombotic effect, and lower risk of complications. However, subcutaneous LMWH injections-commonly administered in the abdomen, arm, or thigh-often cause local side effects such as pain, ecchymosis, and hematoma. The incidence of ecchymosis after injection ranges between 26-89%, and various factors such as injection site, needle size, injection duration, and techniques can influence these outcomes. Cold application is frequently used to reduce injection-related pain and bruising by inducing vasoconstriction, decreasing nerve conduction, and increasing pain tolerance.

In orthopedic surgery patients, limited injection sites due to dressings, casts, or splints may increase the risk of repeated bruising and pain. Although cold compresses have been studied in reducing injection-related complications, no research has evaluated the effect of cold spray prior to LMWH administration in this patient group. Therefore, standardized studies are needed to determine whether cold spray is an effective, practical alternative for reducing pain and ecchymosis following LMWH prophylaxis after orthopedic surgery.

详细描述

Heparin is an anticoagulant used in the surgical prevention of thrombosis and can prevent and treat venous thrombosis by rapidly achieving its anticoagulant effects. Low molecular weight heparin (LMWH), a relatively new anticoagulant developed in the 1970s, has the advantages of high bioavailability, potent antithrombotic effect, a low risk of heparin-induced thrombocytopenia, and fewer bleeding side effects. Therefore, LMWH is increasingly used in clinical practice. Venous thromboembolism is a common complication during and after hospitalization in medical and surgical patients, including orthopedic patients. Without any prophylaxis, the incidence of fatal pulmonary embolism in hospitalized patients is 0.1-0.8% after elective general surgery, 2-3% after elective hip replacement, and 4-7% after hip fracture surgery. Therefore, patients receive heparin for several days or weeks from hospital admission until discharge.

Nurses, in their therapeutic role, administering medications is one of the most fundamental nursing functions requiring knowledge and skill.The basis of medication administration is to ensure patient safety, enhance the beneficial effects of the medication, prevent complications, and increase individual satisfaction and comfort.

The primary route of administration for low molecular weight heparin (LMWH) is subcutaneous injection into the abdominal area, midline of the triceps muscle, or lateral thigh. This method is preferred due to its easy accessibility and slow absorption of the medication. However, local side effects such as pain, ecchymosis (26.6%-88.9%), hematoma (40%-88%), and, in rare cases, tissue sclerosis can occur. Post-injection ecchymosis often occurs between 48 and 72 hours. Factors affecting the pain and bruising caused by subcutaneous injection of LMWH may include injection time; different injection sites; LMWH dose; needle size; slow delivery of heparin to tissues; use of the aspiration airlock technique; and cold application. Cold application has been frequently used to prevent injection-related pain and ecchymosis. In cold applications, when the skin temperature drops to 15 °C, vasoconstriction develops in superficial vessels, and vasodilation develops as the temperature drops even lower. Cold application reduces muscle spasm by slowing down the conduction properties of peripheral nerves and increases pain tolerance. Additionally, vasoconstriction resulting from cold application can reduce blood flow to the tissue, reducing bruising and hematoma formation.

After orthopedic surgery, patients are applied a dressing, bandage, cast, or splint, and post-traumatic bruising or ecchymosis can occur in many areas of the skin. Therefore, injection sites are limited, making rotation between these areas difficult. Using the same area can lead to the formation of new ecchymosis and increased pain sensitivity in the area. There are no studies in the literature on the effects of cold spray applied before SC LMWH application after orthopedic surgery. A more standardized and practical study is needed to evaluate the effects of cold spray on pain and ecchymosis, which can be achieved with cold compresses instead of cold compresses.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Investigator, Outcomes Assessor)

盲法说明

The study employed a single-blind design. To prevent bias in the analysis of the research data, blinding was also applied to the outcomes assessor and statistician. The care provider and researcher in the study were composed of different individuals. When coding the research data, the study groups were coded as A and B, preventing the statistician from knowing which letter represented which group.

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Patients who are:
  • •18 years of age or older
  • •Receiving 1 x 0.4 ml anticoagulant therapy
  • •Are on the first day of LMWH therapy
  • •Have no infection, scar tissue, lipodystrophy, or incision at the injection site
  • •Have not received any other parenteral therapy at the injection site
  • •Are not allergic to cold or heparin
  • •Volunteer to participate in the study

排除标准

  • •Patients were excluded from the study if they were: • Pregnant, • Had any acute or chronic coagulation disorder or hematological disease,
  • •Had a subcutaneous injection into the same area 24 hours prior,
  • •Wanted to withdraw from the study.

研究组 & 干预措施

Cold Spray Application

Experimental

In patients who receive standard and routine subcutaneous low molecular weight heparin (LMWH) prophylaxis after orthopedic surgery, cold spray is applied to the injection site before this injection.

干预措施: Cold Spray Application (Other)

Standart (Routine) Care

No Intervention

This injection is administered without cold application to patients receiving standard and routine subcutaneous low molecular weight heparin (LMWH) prophylaxis after orthopedic surgery.

结局指标

主要结局

Pain Intensity

时间窗: Immediately after each LMWH injection.

Pain intensity at the injection site will be measured using the Visual Analog Scale (VAS). 10-cm VAS scale (0 = no pain, 10 = worst possible pain).

Ecchymosis Area

时间窗: 48 and 72 hours after injection.

The size of ecchymosis at the injection site will be measured using the Opsite-Flexigrid transparent film. Area calculated in cm² by tracing the ecchymosis on the grid.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Şükriye ŞAHİN

Research Assistant

Kocaeli University

研究点 (1)

Loading locations...

相似试验

已完成
不适用
Does flushing of the dialyser with heparin to increase its reuse?
CTRI/2015/10/006310Christian Medical College and Hospital50
进行中(未招募)
1 期
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womedeep vein thrombosispulmonary embolismMedDRA version: 16.1Level: LLTClassification code 10066529Term: Deep vein thrombosis recurrentSystem Organ Class: 100000004866MedDRA version: 16.1Level: LLTClassification code 10066738Term: Recurrent pulmonary embolismSystem Organ Class: 100000004855
EUCTR2012-001505-24-IEThe Rotunda Maternity Hospital850
进行中(未招募)
1 期
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womedeep vein thrombosispulmonary embolismMedDRA version: 18.0Level: LLTClassification code 10066529Term: Deep vein thrombosis recurrentSystem Organ Class: 100000004866MedDRA version: 18.0Level: LLTClassification code 10066738Term: Recurrent pulmonary embolismSystem Organ Class: 100000004855
EUCTR2012-001505-24-BEAcademic Medical Center850
进行中(未招募)
1 期
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womedeep vein thrombosispulmonary embolismMedDRA version: 21.1Level: LLTClassification code 10066529Term: Deep vein thrombosis recurrentSystem Organ Class: 100000004866MedDRA version: 21.1Level: LLTClassification code 10066738Term: Recurrent pulmonary embolismSystem Organ Class: 100000004855
EUCTR2012-001505-24-NLAcademic Medical Center790
进行中(未招募)
1 期
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womedeep vein thrombosispulmonary embolismMedDRA version: 21.1Level: LLTClassification code 10066529Term: Deep vein thrombosis recurrentSystem Organ Class: 100000004866MedDRA version: 21.1Level: LLTClassification code 10066738Term: Recurrent pulmonary embolismSystem Organ Class: 100000004855
EUCTR2012-001505-24-DKAcademic Medical Center1,000
Cold Spray for Pain and Ecchymosis After... | 临床试验